
Genmab (GMAB): EPKINLY Growth vs. Royalty Dependence
Genmab is shifting from a royalty-led model toward proprietary growth, with EPKINLY driving strong sales gains and late-stage oncology assets offering a path to diversify revenue. The stock looks attractive for investors who can tolerate patent-expiry and pipeline-execution risk.

